xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns="http://www.w3.org/TR/REC-html40"> Pharmaceutical sales by therapeutic area

Date: Sat, 24 Feb 2001 11:58:04 -0500

Subject: GlaxoSmithKline’s Strong Performance from Key Therapy Areas and New Products Drives Earnings Per Share Growth to 16% in Sterling (14% CER)

“Vaccines increased 11 percent to $1,280 million—New vaccines, accounting for 63 percent of the total vaccine portfolio, were up 20 percent, boosted by the performance of Infanrix, the company’s DTPa (diphtheria, tetanus and pertussis) range of combination vaccines— growing at 47 percent.” ...

Pharmaceutical sales by therapeutic area

2000

Total USA

Europe RoW

$m CER% $m CER% $m CER% $m CER%

VACCINES 1,280 11 322 (5) 593 11 365 29

Hepatitis 702 (3) 255 (4) 319 (3) 128

(2)

Infanrix 260 47 53 59 149 34

58 84

http://biz.yahoo.com/prnews/010221/glaxosmithkline_earns.html

Press Release

SOURCE: GlaxoSmithKline plc

GlaxoSmithKline’s Strong Performance from Key Therapy Areas and New Products Drives Earnings Per Share Growth to 16% in Sterling (14% CER)

HIGHLIGHTS

· Pharmaceutical sales up 10 percent

· Sales growth in key therapy areas: CNS 16 percent, Respiratory 15 percent, Anti-virals 14 percent

· New products contributed nearly $1.5 billion in growth, up 60 percent

· Avandia sales of $702 million

· Seretide sales of $316 million, US launch of Seretide/Advair planned for

April 2001

· Business performance profits before tax up 11 percent; EPS up 14 percent

LONDON, Feb. 21 /PRNewswire/ -- GlaxoSmithKline plc (NYSE: GSK - news;

“GSK”) today announces its results for the year ended December 31, 2000, summarized below. The merger of Glaxo Wellcome (“GW”) and SmithKline Beecham (“SB”) was completed on December 27, 2000, and the results for 2000 reflect the combined results of the separate GW and SB businesses in 2000.

2000 BUSINESS PERFORMANCE RESULTS

2000 1999 Increase

$m $m CER%

Total Sales 27,480 26,186 9

Trading Profit 7,640 7,133 12

Profit Before Tax 8,097 7,627 11

Earnings Per ADR $1.85 $1.71 14

Business performance results exclude merger items and restructuring costs.

Growth rates are at constant exchange rates (CER) unless otherwise stated.

1999 sales and trading profit exclude Healthcare Services.

Commenting on the performance for the year, Jean-Pierre Garnier, Chief Executive Officer, said:

“These results, achieved while we were separate companies, demonstrate the strength and performance of the two organizations we have brought together to form GSK. Clearly our employees remained focused on maintaining the momentum of our separate businesses, despite the distraction of integration planning, and delivered excellent results. I’m particularly pleased by the performance of Seretide and Avandia. The business is in good shape and GSK is off to a strong start.”

Fourth quarter 2000 -- Sales growth in the fourth quarter was 4 percent, essentially reflecting the impact of wholesaler stocking in the third quarter in the USA. Key products, such as Paxil, Augmentin and Wellbutrin, achieved significantly higher growth in prescription volume than in reported sales, indicating that underlying business performance in the fourth quarter remained strong.

Pharmaceuticals

Pharmaceutical sales of $23,452 million were 85 percent of total sales and grew at 10 percent. With sales of over $4 billion, new products represent 17 percent of pharmaceutical sales and grew 60 percent.

Pharmaceutical sales in the USA, which represents half of GSK’s total pharmaceutical business, grew 15 percent driven by strong performances from all major products. In Europe, pharmaceutical sales growth was 6 percent, while the rest of the world (RoW) was up 8 percent.

Strong growth from key therapy areas: CNS growth driven by Seroxat/Paxil—

In GSK’s largest sales category, CNS, excellent growth of 16 percent to $4,984 million was driven by an outstanding performance from Seroxat/Paxil, which increased by 17 percent to $2,356 million. During 2000, Paxil became the market leader in the US SSRI (selective serotonin reuptake inhibitor) market in new retail prescriptions. Paxil benefited throughout the world from its new indication for Social Anxiety Disorder. GSK’s strategy of broadening the label for new indications continued with filings for Generalized Anxiety Disorder and Post Traumatic Stress Disorder, and the expected launches during 2001 will contribute to further growth of Paxil in the USA. In Europe, where Seroxat continues to be the number one antidepressant, its sales grew by 11 percent to $508 million, while in the RoW growth was 29 percent to $242 million. Paxil was launched in Japan at the end of 2000 and is off to a strong start.

Wellbutrin for depression also made a significant contribution to GSK’s strong CNS performance. In the USA, sales grew 19 percent, and worldwide sales amounted to $687 million. In the company’s migraine portfolio— which achieved sales of $1,189 million, up 5 percent—Imigran/Imitrex remains the global market leader with sales of $1,072 million.

Lamictal for epilepsy grew strongly -- 28 percent to $439 million worldwide and 34 percent in the USA to $210 million—owing to additional promotional resources in the USA.

Three key Respiratory products—Seretide, Flixotide, and Serevent— contributed $623 million in growth—In the Respiratory therapy area, Flixotide/Flovent, up 29 percent to $1,338 million, continues to be the world’s leading treatment for asthma. US sales growth of 57 percent represents an outstanding performance. Seretide achieved sales of $316 million, and continues to be successfully launched in markets around the world. Further Seretide growth will be driven by its US launch planned for April under the trade name Advair. The company expects Seretide/Advair to become the treatment of choice for persistent asthma.

Anti-viral leadership continued with the launch of Trizivir, the first triple combination treatment for HIV/AIDS—The growth of GSK’s HIV products, up 14 percent to $1,740 million, contributed strongly to the performance of the company’s Anti-viral therapy area. Combivir grew 21 percent to $854 million, while Trizivir, the first triple combination HIV therapy, was launched in the USA in December 2000 and subsequently in the UK, France and Switzerland. Strong performances from Ziagen and Agenerase, with combined sales of over $300 million, reflect the broadness of the HIV portfolio. In the herpes franchise, Valtrex, up 32 percent to $368 million, gained significant market share owing to the convenience of its once-daily dosing.

Confirmed success of Avandia drove the Metabolic & GI business—Avandia for the treatment of Type 2 diabetes continues to fulfill its outstanding potential, achieving sales of $702 million. With sales in the US of $658 million and a 55 percent market share, Avandia has been prescribed to over 1.7 million patients. In 2001, further growth is expected from Avandia as it continues to rollout in Europe and RoW. Lotronex, a treatment for irritable bowel syndrome, was launched in the USA in March 2000 and generated sales of $55 million before being withdrawn in November 2000.

Augmentin retained momentum in Anti-bacterials, with long-term opportunities for growth—The highlight of the performance in the Anti-bacterial therapy area was Augmentin in the USA, where it grew by 13 percent to $1,102 million, benefiting from increased awareness of its effectiveness in treating drug-resistant bacteria. Worldwide, Augmentin achieved total sales in 2000 of $1,853 million, up 8 percent.

Vaccines increased 11 percent to $1,280 million—New vaccines, accounting for 63 percent of the total vaccine portfolio, were up 20 percent, boosted by the performance of Infanrix, the company’s DTPa (diphtheria, tetanus and pertussis) range of combination vaccines—growing at 47 percent.

Consumer Healthcare

Consumer Healthcare sales grew 3 percent; trading profit grew 7 percent—

In the USA, consumer sales decreased 3 percent, reflecting the impact of private label smoking control products and a mild ‘flu season.

Worldwide sales of Oral Care products rose 6 percent to $976 million, with sales growth of 13 percent in the Aquafresh product line. Nutritional Healthcare products increased 9 percent to $813 million. Sales growth was primarily driven in the UK by the strength of Lucozade ‘Sport’ and by the success of Ribena. Worldwide sales of over-the-counter (OTC) medicines totalled $2,210 million, down 1 percent primarily owing to an 8 percent decline in the smoking control franchise.

Consumer Healthcare set to benefit from Block Drug acquisition—In January 2001, GSK completed the acquisition of Block Drug, the manufacturer of Sensodyne toothpaste and other oral healthcare and consumer products, for $1.24 billion. This strategic acquisition will enhance the Consumer Healthcare performance through a significant increase in sales and sales synergies through geographic expansion of major brands, significant cost savings, and other improvements in trading margins.

Dividend

Both GW and SB had already announced dividends for the period up to 31^st December 2000. GW will pay a second interim dividend and SB a fourth interim dividend on 17^th April 2001.

GSK—one of the world’s leading research-based pharmaceutical and

healthcare companies—is committed to improving the quality of human life

by enabling people to do more, feel better and live longer. For company

information, visit GSK on the World Wide Web at www.gsk.com. Inquiries:

UK Media Inquiries Martin Sutton (020) 8966 8000

Philip Thomson (020) 8966 8000

Alan Chandler (020) 8975 2290

US Media Inquiries Nancy Pekarek (215) 751 7709

Mary Anne Rhyne (919) 483 2839

European Analyst/Investor

Inquiries Jennie Younger (020) 8966 8378

Duncan Learmouth (020) 8966 5961

Joan Toohill (020) 8966 8715

Anita Kidgell (020) 8966 8369

US Analyst/ Investor

Inquiries Frank Murdolo (212) 308 5185

Tom Curry (215) 751 5419

GSK prepares its results in pounds sterling. Accordingly, the results announcement is issued in pounds sterling and is available on “Corporate Home” at www.gsk.com. This document is a convenience translation in US$.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’s operations include generic and brand competition for existing products, ability to integrate the businesses and realize synergies and cost savings, difficulties and uncertainties inherent in new product development, pricing pressures, changes in government laws and regulations, efficacy or safety concerns over marketed products, adverse outcome of material legal proceedings, changes in tax laws, and economic factors over which GSK has no control including changes in inflation, interest rates and foreign currency exchange rates and controls.

PROFIT AND LOSS ACCOUNT

2000

Merger,

restructuring

Business and disposal of

performance subsidiaries Total

2000 1999 2000 1999 2000 1999

$m $m CER% $m $m $m $m

----- ----- ----- ----- ----- ----- -----

SALES

Retained businesses

· Pharma-

ceuticals 23,452 22,061 10 - - 23,452 22,061

· Consumer

Healthcare 4,028 4,125 3 - - 4,028 4,125

------ ------ ----- ----- ------- -------

27,480 26,186 9 - - 27,480 26,186

· Healthcare

Services - 1,024 - - - 1,024

------- ------- ----- ----- ------- -------

Total Sales 27,480 27,210 - - 27,480 27,210

------- ------- ----- ----- ------- -------

Cost of sales (5,793) (5,669) (8) (230) (646) (6,023) (6,315)

Selling,

general and

administration (10,232) (9,723) (9) (614) (71) (10,846) (9,794)

Research and

development (3,815) (3,702) (7) (24) - (3,839) (3,702)

------- ------- ----- ----- ------- -------

Operating costs

· retained

businesses (19,840) (19,094) (868) (717) (20,708) (19,811)

------- ------- ----- ----- ------- -------

Operating costs

· Healthcare

Services - (983) - (49) - (1,032)

TRADING PROFIT

Retained businesses

· Pharma-

ceuticals 6,963 6,436 13 (800) (685) 6,163 5,751

· Consumer

Healthcare 677 656 7 (68) (32) 609 624

------- ------- ----- ----- ------- -------

7,640 7,092 12 (868) (717) 6,772 6,375

· Healthcare

Services - 41 - (49) - (8)

------- ------- ----- ----- ------- -------

Total Trading

Profit 7,640 7,133 12 (868) (766) 6,772 6,367

Other operating

income/(expense) 416 669 - - 416 669

------- ------- ----- ----- ------- -------

Operating profit 8,056 7,802 (868) (766) 7,188 7,036

Disposal of associates 219 63 - - 219 63 Profits/(losses)

of associates 99 24 (12) (13) 87 11

Divestments - - 2,131 15 2,131 15

Merger transaction

costs - - (184) - (184) -

------- ------- ----- ----- ------- -------

Profit before

interest 8,374 7,889 11 1,067 (764) 9,441 7,125

Net interest

payable (277) (262) - - (277) (262)

------- ------- ----- ----- ------- -------

PROFIT BEFORE

TAXATION 8,097 7,627 11 1,067 (764) 9,164 6,863

Taxation (2,210) (2,150) (372) 176 (2,582) (1,974)

------- ------- ----- ----- ------- -------

Profit after

taxation 5,887 5,477 12 695 (588) 6,582 4,889

Minority interests (183) (178) - - (183) (178)

Preference share

dividends (85) (79) - - (85) (79)

------- ------- ----- ----- ------- -------

EARNINGS 5,619 5,220 13 695 (588) 6,314 4,632

======= ======= ===== ===== ======= =======

EARNINGS PER ADR $1.85 $1.71 14 $2.08 $1.51

======= ======= ======= =======

To illustrate “Business performance”, merger items and restructuring costs in 2000 and restructuring costs and business disposals in 1999 have been excluded and an adjusted EPS presented.

Appropriations of profit attributable to shareholders are set out under

“Appropriations”. PROFIT AND LOSS ACCOUNT

Q4 2000

Merger,

restructuring

Business and disposal of

performance subsidiaries Total

Q4 Q4 Q4 Q4 Q4 Q4

2000 1999 2000 1999 2000 1999

$m $m CER% $m $m $m $m

----- ----- ----- ----- ----- ----- -----

SALES

Retained businesses

· Pharma-

ceuticals 6,319 6,388 5 - - 6,319 6,388

· Consumer

Healthcare 1,064 1,154 (1) - - 1,064 1,154

------ ------ ----- ----- ------ ------

7,383 7,542 4 - - 7,383 7,542

· Healthcare

Services - 7 - - - 7

------ ------ ----- ----- ------ ------

Total Sales 7,383 7,549 - - 7,383 7,549

------ ------ ----- ----- ------ ------

Cost of sales (1,538) (1,612) (1) (134) (271) (1,672) (1,883)

Selling,

general and

administration (2,726) (2,865) 2 (271) (29) (2,997) (2,894)

Research and

development (1,052) (1,107) (2) (20) - (1,072) (1,107)

------ ------ ----- ----- ------ ------

Operating costs

· retained

businesses (5,316) (5,584) (425) (300) (5,741) (5,884)

------ ------ ----- ----- ------ ------

Operating costs

· Healthcare

Services - (7) - (39) - (46)

TRADING PROFIT

Retained businesses

· Pharma-

ceuticals 1,858 1,786 14 (422) (274) 1,436 1,512

· Consumer

Healthcare 209 172 29 (3) (26) 206 146

------ ------ ----- ----- ------ ------

2,067 1,958 15 (425) (300) 1,642 1,658

· Healthcare

Services - - - (39) - (39)

------ ------ ----- ----- ------ ------

Total Trading

Profit 2,067 1,958 15 (425) (339) 1,642 1,619

Other operating

income/(expense) 222 310 - - 222 310

------ ------ ----- ----- ------ ------

Operating profit 2,289 2,268 (425) (339) 1,864 1,929

Disposal of associates (3) - - - (3) - Profits/(losses)

of associates 20 39 (1) (13) 19 26

Divestments - - 2,131 15 2,131 15

Merger transaction

costs - - (113) - (113) -

------ ------ ----- ----- ------ ------

Profit before

interest 2,306 2,307 9 1,592 (337) 3,898 1,970

Net interest

payable (64) (85) - - (64) (85)

------ ------ ----- ----- ------ ------

PROFIT BEFORE

TAXATION 2,242 2,222 10 1,592 (337) 3,834 1,885

Taxation (612) (619) (489) 58 (1,101) (561)

------ ------ ----- ----- ------ ------

Profit after

taxation 1,630 1,603 11 1,103 (279) 2,733 1,324

Minority interests (50) (46) - - (50) (46)

Preference share

dividends (22) (21) - - (22) (21)

------ ------ ----- ----- ------ ------

EARNINGS 1,558 1,536 12 1,103 (279) 2,661 1,257

====== ====== ===== ===== ====== ======

EARNINGS PER ADR $0.51 $0.51 12 $0.88 $0.41

====== ====== ====== ======

To illustrate “Business performance”, merger items and restructuring

costs in 2000 and restructuring costs in 1999 have been excluded and an

adjusted EPS presented. Pharmaceutical sales by

therapeutic area

2000

Total USA Europe RoW

$m CER% $m CER% $m CER% $m CER%

------------ ------------ ------------ -----------

CNS 4,984 16 3,507 15 1,031 16 446 28

Depression 3,043 17 2,272 18 508 11 263 31

Seroxat/Paxil 2,356 17 1,606 18 508 11 242 29

Wellbutrin 687 19 666 19 - - 21 58

Migraine 1,189 5 894 5 231 - 64 11

Imigran/Imitrex 1,072 3 824 4 193 (2) 55 6

Naramig/Amerge 117 20 70 20 38 15 9 51

Lamictal 439 28 210 34 176 20 53 35

Requip 88 20 40 19 46 20 2 26

Zyban 175 54 91 1 52 >100 32

RESPIRATORY 4,239 15 1,705 26 1,698 9 836 10

Flixotide/

Flovent 1,338 29 629 57 464 2 245 49

Serevent 945 8 502 24 385 (6) 58 14

Seretide 316 >100 - - 272 >100 44

>100

Flixonase/

Flonase 620 16 447 18 68 10 105 14

Ventolin 521 (7) 47 (21) 226 (5) 248 (6)

Becotide 312 (25) 6 (82) 231 (12) 75 (40)

ANTI-BACTERIALS 3,758 2 1,736 7 1,072 (4) 950 1

Augmentin 1,853 8 1,102 13 486 (3) 265 9

Zinnat/Ceftin 654 - 310 (7) 172 3 172 10

Fortum 324 (9) 61 (17) 134 (1) 129 (14)

Amoxil 302 1 79 55 93 (18) 130 -

ANTI-VIRALS 2,886 14 1,394 17 807 13 685 12

HIV 1,740 14 1,043 16 525 18 172 (9)

Trizivir 11 >100 9 >100 2 >100

- -

Combivir 854 21 524 17 263 38 67 (5)

Epivir 470 (7) 250 - 152 (9) 68 (22)

Retrovir 92 (30) 38 (22) 35 (35) 19 (33)

Ziagen 234 75 152 46 67 >100 15

>100

Agenerase 79 60 70 52 6 81 3

>100

Herpes 936 5 286 14 246 1 404 3

Valtrex 368 32 224 24 88 22 56

>100

Zovirax 568 (7) 62 (12) 158 (8) 348 (6)

Zeffix 106 >100 8 >100 10 >100

88 >100

Relenza 49 97 21 29 9 51 19

>100

METABOLIC &

GASTRO-

INTESTINAL 1,873 33 903 >100 377 (13) 593

Avandia 702 >100 658 >100 12 >100

32 >100

Zantac 874 (11) 181 (18) 287 (16) 406 (4)

Lotronex 55 >100 55 >100 - - -

VACCINES 1,280 11 322 (5) 593 11 365 29

Hepatitis 702 (3) 255 (4) 319 (3) 128 (2)

Infanrix 260 47 53 59 149 34 58 84

ONCOLOGY &

EMESIS 1,079 11 758 12 196 9 125 10

Zofran 746 13 514 15 141 12 91 6

Hycamtin 144 1 96 (5) 35 6 13 40

CARDIOVASCULAR 704 - 429 (8) 182 19 93 10

Coreg 225 11 225 17 - - - -

ARTHRITIS

(Relafen) 319 (28) 278 (30) 26 (7) 15 (23)

DERMATOLOGICALS 378 (4) 53 (20) 94 (5) 231 -

OTHER 1,272 (2) 260 (6) 346 (7) 666 2

------------- ------------- ------------ ------------

TOTAL SALES

CONTINUING

BUSINESS 22,772 11 11,345 15 6,422 6 5,005 9

Divested

products 680 (2) 367 (1) 65 (5) 248 (3)

Famvir 231 11 174 20 27 (13) 30 (5)

Kytril 333 (7) 187 (14) 38 1 108 2

Other 116 (9) 6 (40) - - 110 (7)

------------- ------------- ------------ ------------

TOTAL

PHARMACEUTICAL

SALES 23,452 10 11,712 (3) 6,487 6 5,253 8

============= ============= ============ ============

Pharmaceutical sales by therapeutic area

Q4 2000

Total USA Europe RoW

$m CER% $m CER% $m CER% $m CER%

------------ ------------ ------------ -----------

CNS 1,337 5 931 1 276 7 130 31

Depression 801 3 583 (1) 137 - 81 45

Seroxat/Paxil 617 - 405 (5) 137 - 75 45

Wellbutrin 184 12 178 11 - - 6 48

Migraine 327 - 254 2 55 (10) 18 14

Imigran/Imitrex 296 - 236 2 45 (12) 15 11

Naramig/Amerge 31 4 18 4 10 (2) 3 42

Lamictal 120 20 61 26 45 14 14 16

Requip 25 3 12 6 14 1 (1) -

Zyban 53 76 22 (12) 21 >100 10

RESPIRATORY 1,185 14 502 25 448 7 235 9

Flixotide/

Flovent 391 28 205 64 113 (6) 73 36

Serevent 270 10 157 30 100 (8) 13 (1)

Seretide 114 >100 - - 93 >100 21

>100

Flixonase/

Flonase 152 5 113 5 14 4 25 4

Ventolin 142 (10) 16 (20) 58 (8) 68 (8)

Becotide 73 (34) (2) >(100) 57 (19) 18

(41)

ANTI-BACTERIALS 1,060 (7) 532 (3) 285 (12) 243 (9)

Augmentin 547 (2) 350 4 130 (12) 67 (6)

Zinnat/Ceftin 200 (4) 104 (9) 50 4 46 (2)

Fortum 82 (16) 15 (30) 32 (11) 35 (16)

Amoxil 76 (19) 16 3 25 (35) 35 (10)

ANTI-VIRALS 792 11 384 11 199 4 209 18

HIV 471 12 284 13 135 13 52 -

Trizivir 11 >100 9 >100 2 >100

- -

Combivir 233 18 141 16 70 23 22 16

Epivir 125 (3) 70 6 36 (7) 19 (20)

Retrovir 23 (22) 10 (16) 8 (26) 5 (27)

Ziagen 60 31 38 13 18 64 4 82

Agenerase 19 - 16 (11) 1 41 2

>100

Herpes 249 3 81 16 55 (8) 113 2

Valtrex 115 51 64 28 22 19 29

>100

Zovirax 134 (18) 17 (13) 33 (19) 84 (19)

Zeffix 34 >100 4 >100 2 >100

28 >100

Relenza 18 (23) 1 (93) 1 (76) 16

>100

METABOLIC & GASTRO-

INTESTINAL 501 23 238 86 95 (11) 168 2

Avandia 206 >100 187 >100 6 >100

13 >100

Zantac 224 (16) 42 (33) 70 (16) 112 (8)

Lotronex 6 >100 6 >100 - - -

VACCINES 314 5 76 17 143 (8) 95 23

Hepatitis 165 (10) 61 7 73 (21) 31 (6)

Infanrix 67 20 14 88 37 12 16 8

ONCOLOGY & EMESIS 295 11 211 16 48 (2) 36

Zofran 198 13 138 18 35 6 25 3

Hycamtin 42 (1) 30 1 9 (11) 3 24

CARDIOVASCULAR 180 (3) 109 (12) 45 18 26 3

Coreg 59 23 59 23 - - - -

ARTHRITIS (Relafen) 71 (31) 62 (30) 6 (40) 3 (31)

DERMATOLOGICALS 98 (5) 14 (17) 22 (2) 62 (3)

OTHER 336 8 72 26 90 (11) 174 16

------------ ------------ ------------ ------------

TOTAL SALES

CONTINUING

BUSINESS 6,169 6 3,131 9 1,657 (1) 1,381 8

Divested

products 150 (26) 63 (40) 14 (18) 73 (11)

Famvir 45 (23) 32 (25) 5 (27) 8 (10)

Kytril 70 (32) 30 (51) 9 (11) 31 (8)

Other 35 (15) 1 (40) - - 34 (14)

------------ ------------ ------------ ------------

TOTAL

PHARMACEUTICAL

SALES 6,319 5 3,194 7 1,671 (1) 1,454 7

============ ============ ============ ============

SOURCE: GlaxoSmithKline plc

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.

Primary Links

User login